NASDAQ: PLSEPulse Biosciences Inc Stock
$17.29-0.45 (-2.54%)
Updated Apr 21, 2025
PLSE Price
$17.29
Fair Value Price
$1.87
Market Cap
$1.16B
52 Week Low
$6.60
52 Week High
$25.00
P/E
-18.79x
P/B
10.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$53.59M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.15
Operating Cash Flow
-$36M
Beta
1.29
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PLSE Overview
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PLSE's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
PLSE
Ranked#37 of 41
Ranked#37 of 41
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $4.91 | B | |
| $89.60 | B | |
| $58.31 | B |
Be the first to know about important PLSE news, forecast changes, insider trades & much more!
PLSE News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PLSE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PLSE ($17.29) is overvalued by 825.14% relative to our estimate of its Fair Value price of $1.87 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PLSE ($17.29) is not significantly undervalued (825.14%) relative to our estimate of its Fair Value price of $1.87 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PLSE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PLSE due diligence checks available for Premium users.
Valuation
PLSE fair value
Fair Value of PLSE stock based on Discounted Cash Flow (DCF)
Price
$17.29
Fair Value
$1.87
Overvalued by
825.14%
PLSE ($17.29) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PLSE ($17.29) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PLSE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PLSE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-18.79x
Industry
38.94x
Market
27.14x
PLSE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.13x
Industry
3.49x
PLSE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PLSE's financial health
Profit margin
Revenue
$0.0
Net Income
-$19.4M
Profit Margin
0%
PLSE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$132.5M
Liabilities
$17.6M
Debt to equity
0.15
PLSE's short-term assets ($119.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PLSE's short-term assets ($119.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PLSE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PLSE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.1M
Investing
-$53.0k
Financing
$48.2M
PLSE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PLSE vs Medical Stocks
Pulse Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.